NEW YORK, NY, USA I 13, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Because a subset of these patients actually have DNA damage repair mutations, we know that adding a PARP inhibitor in the setting of progression has been associated with improvements in survival ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

东京国家癌症中心研究所基因组应激信号实验室等多单位的研究人员 Kimiyoshi Yano、Megumi Kato 等，在《Cell Death Discovery》期刊上发表了题为 “PARP inhibition-associated heterochromatin confers increased DNA replication stress ... 包括 A549、H1299、H2172 ...

Azenosertib Clinical Results ZN-c3-001 ZN-c3-001 is a Phase 1, dose-escalation study that evaluated azenosertib monotherapy in solid tumors across continuous and intermittent dosing schedules.

This extension builds on a 2024 agreement to define and discover biomarkers within the DNA damage response (DDR ... Debiopharm's WEE1 asset is currently in Phase 1 clinical research and is ...

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against ...

The captured regions totaled 1 ... DNA damage response (DDR), ensuring genomic stability. The absence of these domains compromises the protein’s stability and increases degradation susceptibility, ...

TAIPEI -- Taiwan's remaining undersea cable link to the Matsu Islands near China was completely disconnected early Wednesday, the government said, adding to a string of such issues and raising ...